$TVTX
Travere Therapeutics, Inc. Stock $tvtx

$tvtx Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000162828016020847 Filed on November 04, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q4
Revenue	$37.33M	$33.95M	$30.45M
YoY Change	22.6%	21.21%	116.17%
Cost Of Revenue	$1.200M	$1.573M	$760.0K
YoY Change	57.89%	206.63%	123.53%
Gross Profit	$36.12M	$32.37M	$29.69M
YoY Change	21.66%	17.75%	115.93%
Gross Profit Margin	96.77%	95.37%	97.51%
Selling, General & Admin	$22.58M	$23.47M	$18.95M
YoY Change	19.16%	5.19%	2.65%
% of Gross Profit	62.51%	72.49%	63.83%
Research & Development	$20.00M	$18.41M	$15.37M
YoY Change	30.12%	30.93%	8.32%
% of Gross Profit	55.37%	56.88%	51.77%
Depreciation & Amortization	$4.190M	$4.090M	$3.970M
YoY Change	5.54%	5.41%	113.44%
% of Gross Profit	11.6%	12.63%	13.37%
Operating Expenses	$55.55M	$54.32M	$45.65M
YoY Change	21.68%	11.99%	39.26%
Operating Profit	-$18.22M	-$20.37M	-$15.20M
YoY Change	19.85%	-0.6%	-18.68%
Interest Expense	-$1.290M	-$299.0K	-$4.210M
YoY Change	-69.36%	-56.98%	-59.24%
% of Operating Profit
Other Income/Expense, Net	-$5.935M	$10.27M	$2.210M
YoY Change	-368.55%	-93.77%	-121.39%
Pretax Income	-$12.29M	-$30.65M	-$12.99M
YoY Change	-5.44%	-121.23%	-55.23%
Income Tax	-$3.684M	$6.467M	-$10.53M
% Of Pretax Income
Net Earnings	-$8.603M	-$37.11M	-$2.469M
YoY Change	248.44%	-135.15%	-91.49%
Net Earnings / Revenue	-23.05%	-109.33%	-8.11%
Basic Earnings Per Share	-$0.23	-$1.00	-$0.07
Diluted Earnings Per Share	-$0.39	-$1.00	-$0.14
COMMON SHARES
Basic Shares Outstanding	37.73M shares	36.98M shares	36.15M shares
Diluted Shares Outstanding		36.98M shares

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$255.9M	$274.3M	$229.6M
YoY Change	11.44%	16.59%	727.1%
Cash & Equivalents	$41.00M	$23.90M	$37.81M
Short-Term Investments	$214.9M	$250.4M	$191.8M
Other Short-Term Assets	$8.300M	$3.600M	$10.50M
YoY Change	-20.95%	80.0%	1212.5%
Inventory	$2.826M	$3.253M	$2.536M
Prepaid Expenses
Receivables	$18.51M	$14.96M	$12.46M
Other Receivables	$46.90M	$46.50M	$46.80M
Total Short-Term Assets	$332.4M	$342.6M	$301.9M
YoY Change	10.08%	14.21%	708.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.587M	$382.0K	$428.0K
YoY Change	504.44%	-20.08%	-36.21%
Goodwill	$936.0K	$936.0K	$936.0K
YoY Change	0.0%	0.0%	0.0%
Intangibles	$182.0M		$161.5M
YoY Change	12.7%
Long-Term Investments
YoY Change
Other Assets	$7.364M	$1.974M	$1.859M
YoY Change	296.13%	-1.6%	-17.92%
Total Long-Term Assets	$192.9M	$189.8M	$210.3M
YoY Change	-8.27%	-10.32%	114.32%
TOTAL ASSETS
Total Short-Term Assets	$332.4M	$342.6M	$301.9M
Total Long-Term Assets	$192.9M	$189.8M	$210.3M
Total Assets	$525.3M	$532.4M	$512.3M
YoY Change	2.54%	4.06%	278.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.522M	$3.066M	$7.639M
YoY Change	-1.53%	-37.34%	7.23%
Accrued Expenses	$33.31M	$40.38M	$23.82M
YoY Change	39.83%	80.91%	-14.57%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$83.26M	$85.99M	$86.98M
YoY Change	-4.28%	-15.65%	-19.12%
LONG-TERM LIABILITIES
Long-Term Debt	$44.40M	$44.30M	$43.80M
YoY Change	1.37%	1.37%	1.15%
Other Long-Term Liabilities	$4.010M	$2.461M	$3.066M
YoY Change	30.79%	-82.31%	89.61%
Total Long-Term Liabilities	$4.010M	$2.461M	$3.066M
YoY Change	30.79%	-82.31%	89.61%
TOTAL LIABILITIES
Total Short-Term Liabilities	$83.26M	$85.99M	$86.98M
Total Long-Term Liabilities	$4.010M	$2.461M	$3.066M
Total Liabilities	$217.5M	$224.8M	$212.3M
YoY Change	2.46%	1.91%	22.91%
SHAREHOLDERS EQUITY
Retained Earnings	-$113.1M	-$104.5M	-$65.15M
YoY Change	73.52%	66.63%	-63.64%
Common Stock	$421.3M	$412.4M	$365.8M
YoY Change	15.17%	16.55%	159.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)			$0.00
YoY Change			-100.0%
Treasury Stock Shares			0.000 shares
Shareholders Equity	$307.8M	$307.6M	$300.0M
YoY Change
Total Liabilities & Shareholders Equity	$525.3M	$532.4M	$512.3M
YoY Change	2.54%	4.06%	278.14%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q4
OPERATING ACTIVITIES
Net Income	-$8.603M	-$37.11M	-$2.469M
YoY Change	248.44%	-135.15%	-91.49%
Depreciation, Depletion And Amortization	$4.190M	$4.090M	$3.970M
YoY Change	5.54%	5.41%	113.44%
Cash From Operating Activities	-$8.490M	$4.630M	-$3.550M
YoY Change	139.15%	191.19%	-60.95%
INVESTING ACTIVITIES
Capital Expenditures	-$4.230M	-$2.780M	-$1.720M
YoY Change	145.93%	-28.35%	2050.0%
Acquisitions
YoY Change
Other Investing Activities	$34.70M	-$3.270M	-$98.74M
YoY Change	-135.14%	-105.94%	-4916.59%
Cash From Investing Activities	$30.47M	-$6.050M	-$100.5M
YoY Change	-130.33%	-111.83%	-5199.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-5.050M	4.040M	1.230M
YoY Change	-510.57%	-110.13%	-332.08%
NET CHANGE
Cash From Operating Activities	-8.490M	4.630M	-3.550M
Cash From Investing Activities	30.47M	-6.050M	-100.5M
Cash From Financing Activities	-5.050M	4.040M	1.230M
Net Change In Cash	16.93M	2.620M	-102.8M
YoY Change	-116.47%	-79.6%	1243.53%
FREE CASH FLOW
Cash From Operating Activities	-$8.490M	$4.630M	-$3.550M
Capital Expenditures	-$4.230M	-$2.780M	-$1.720M
Free Cash Flow	-$4.260M	$7.410M	-$1.830M
YoY Change	132.79%	35.47%	-79.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001438533
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37732329	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2016Q3	dei	Entity Number Of Employees EntityNumberOfEmployees	135	Employee
	dei	Entity Registrant Name EntityRegistrantName	Retrophin, Inc.
	dei	Trading Symbol TradingSymbol	rtrx
CY2015Q4	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	964000	USD
CY2016Q3	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	4164000	USD
CY2015Q4	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	4281000	USD
CY2016Q3	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	6694000	USD
CY2015Q4	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	2704000	USD
CY2016Q3	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	1417000	USD
CY2015Q4	rtrx	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	8885000	USD
CY2016Q3	rtrx	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	8281000	USD
CY2015Q4	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	4688000	USD
CY2016Q3	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	13194000	USD
CY2015Q4	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	13754000	USD
CY2016Q3	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	6570000	USD
CY2015Q4	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	45267000	USD
CY2016Q3	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	75370000	USD
CY2015Q3	rtrx	Bargain Purchase Gain BargainPurchaseGain	0	USD
	rtrx	Bargain Purchase Gain BargainPurchaseGain	49063000	USD
CY2016Q3	rtrx	Bargain Purchase Gain BargainPurchaseGain	0	USD
	rtrx	Bargain Purchase Gain BargainPurchaseGain	0	USD
	rtrx	Business Combination Contingent Consideration Arrangements Changein Amountof Contingent Consideration Payment BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationPayment	203000	USD
	rtrx	Business Combination Contingent Consideration Arrangements Changein Amountof Contingent Consideration Payment BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationPayment	772000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-853000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	7000000	USD
CY2015Q3	rtrx	Change In Fair Value Of Derivative Instruments ChangeInFairValueOfDerivativeInstruments	-29991000	USD
CY2015Q3	rtrx	Change In Fair Value Of Derivative Instruments In Shares ChangeInFairValueOfDerivativeInstrumentsInShares	0	shares
CY2016Q3	rtrx	Change In Fair Value Of Derivative Instruments In Shares ChangeInFairValueOfDerivativeInstrumentsInShares	0	shares
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	7026000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	10741000	USD
	rtrx	Classof Warrantor Right Changein Fair Value ClassofWarrantorRightChangeinFairValue	2900000	USD
CY2016Q3	rtrx	Classof Warrantor Right Common Stock Issued Upon Exerciseof Warrants ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants	882533	shares
	rtrx	Classof Warrantor Right Common Stock Issued Upon Exerciseof Warrants ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants	897533	shares
CY2016Q3	rtrx	Contractual Obligation Due In Rolling After Year Five ContractualObligationDueInRollingAfterYearFive	5019000	USD
CY2016Q3	rtrx	Contractual Obligation Due In Rolling Year Four And Five ContractualObligationDueInRollingYearFourAndFive	3127000	USD
CY2016Q3	rtrx	Contractual Obligation Due In Rolling Year Two And Three ContractualObligationDueInRollingYearTwoAndThree	54188000	USD
CY2016Q3	rtrx	Contractual Obligation Next Rolling Twelve Months ContractualObligationNextRollingTwelveMonths	4641000	USD
	rtrx	Derivative Financial Instruments Warrants Issued Recorded In Interest Expense DerivativeFinancialInstrumentsWarrantsIssuedRecordedInInterestExpense	1050000	USD
	rtrx	Derivative Financial Instruments Warrants Issued Recorded In Interest Expense DerivativeFinancialInstrumentsWarrantsIssuedRecordedInInterestExpense	0	USD
CY2015Q3	rtrx	Early Payment Penalty EarlyPaymentPenalty	0	USD
	rtrx	Early Payment Penalty EarlyPaymentPenalty	2250000	USD
CY2016Q3	rtrx	Early Payment Penalty EarlyPaymentPenalty	0	USD
	rtrx	Early Payment Penalty EarlyPaymentPenalty	0	USD
CY2015Q3	rtrx	Finance Expense FinanceExpense	0	USD
	rtrx	Finance Expense FinanceExpense	600000	USD
CY2016Q3	rtrx	Finance Expense FinanceExpense	0	USD
	rtrx	Finance Expense FinanceExpense	0	USD
	rtrx	Gain Loss Upon Divestiture Of Assets GainLossUponDivestitureOfAssets	140004000	USD
	rtrx	Gain Loss Upon Divestiture Of Assets GainLossUponDivestitureOfAssets	0	USD
	rtrx	Gain Loss Upon Divestiture Of Assetsto Company GainLossUponDivestitureOfAssetstoCompany	914000	USD
	rtrx	Gain Loss Upon Divestiture Of Assetsto Company GainLossUponDivestitureOfAssetstoCompany	0	USD
CY2015Q4	rtrx	Government Rebates Payable GovernmentRebatesPayable	3158000	USD
CY2016Q3	rtrx	Government Rebates Payable GovernmentRebatesPayable	4470000	USD
	rtrx	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-32000	USD
	rtrx	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	0	USD
	rtrx	Interest Receivablefrom Notes Receivable InterestReceivablefromNotesReceivable	0	USD
	rtrx	Interest Receivablefrom Notes Receivable InterestReceivablefromNotesReceivable	1605000	USD
	rtrx	Legal Accrual Reversal LegalAccrualReversal	0	USD
	rtrx	Legal Accrual Reversal LegalAccrualReversal	2967000	USD
	rtrx	Noncash Interest Expense NoncashInterestExpense	1818000	USD
	rtrx	Noncash Interest Expense NoncashInterestExpense	1551000	USD
	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	1500000	USD
	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	1500000	USD
	rtrx	Paymentsto Security Deposits PaymentstoSecurityDeposits	0	USD
	rtrx	Paymentsto Security Deposits PaymentstoSecurityDeposits	115000	USD
CY2015Q4	rtrx	Prepaid Taxes Noncurrent PrepaidTaxesNoncurrent	0	USD
CY2016Q3	rtrx	Prepaid Taxes Noncurrent PrepaidTaxesNoncurrent	3240000	USD
	rtrx	Proceedsfrom Maturityof Note Receivable ProceedsfromMaturityofNoteReceivable	0	USD
	rtrx	Proceedsfrom Maturityof Note Receivable ProceedsfromMaturityofNoteReceivable	47500000	USD
CY2016Q3	rtrx	Reclassification Of Derivative Liability To Equity ReclassificationOfDerivativeLiabilityToEquity	14500000	USD
	rtrx	Reclassification Of Derivative Liability To Equity ReclassificationOfDerivativeLiabilityToEquity	14700000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7639000	USD
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3066000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	7026000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12458000	USD
CY2016Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14955000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23820000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9417000	USD
CY2016Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	40376000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	882000	USD
CY2016Q3	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	4050000	USD
CY2015Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2000000	USD
CY2016Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2000000	USD
CY2015Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	7143000	USD
CY2016Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6387000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-682000	USD
CY2016Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-304000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	365802000	USD
CY2016Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	412348000	USD
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8181000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18748000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7748000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22034000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1175000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	491000	USD
CY2015Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3875000	USD
CY2016Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4069000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	11864000	USD
CY2015Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1800000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3800000	shares
CY2016Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11400000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10800000	shares
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	4710000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2015Q4	us-gaap	Assets Assets	512264000	USD
CY2016Q3	us-gaap	Assets Assets	532420000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	301932000	USD
CY2016Q3	us-gaap	Assets Current AssetsCurrent	342590000	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	191799000	USD
CY2016Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	250408000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	8000	USD
CY2016Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	42000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	651000	USD
CY2016Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	286000	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	192442000	USD
CY2016Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	250652000	USD
CY2015Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	191799000	USD
CY2016Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	250408000	USD
	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	-293000	USD
	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	11000	USD
CY2015Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	6900000	USD
CY2015Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	6906000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.67
CY2016Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	5256000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	10741000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18204000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	140596000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37805000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23895000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	122392000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-13910000	USD
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2665548	shares
CY2016Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1768015	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36465853	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37703996	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36465853	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37703996	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	104716000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	115319000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-36788000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39678000	USD
CY2016Q3	us-gaap	Contractual Obligation ContractualObligation	66975000	USD
CY2015Q4	us-gaap	Convertible Debt ConvertibleDebt	43766000	USD
CY2016Q3	us-gaap	Convertible Debt ConvertibleDebt	44257000	USD
CY2016Q3	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	74700000	USD
CY2015Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	513000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1424000	USD
CY2016Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1573000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3351000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-11791000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-10999000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	24328000	USD
CY2016Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	8462000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9417000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11953000	USD
CY2015Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	38810000	USD
CY2016Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	28960000	USD
CY2015Q3	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	518000	USD
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	1553000	USD
CY2016Q3	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.95
CY2016Q3	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	834000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	-439000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.07
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.78
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.30
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.07
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-57000	USD
CY2015Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.269
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.011
CY2016Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.211
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.132
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2015Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-29991000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	36180000	USD
CY2016Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	10126000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4849000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	17560000	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	29424000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	179096000	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	212722000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	161536000	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	183298000	USD
CY2015Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	14000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	8000	USD
CY2016Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	17000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	19000	USD
CY2015Q3	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	140004000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	140004000	USD
CY2016Q3	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-112000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2015Q3	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	15500000	USD
CY2016Q3	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2015Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4151000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4151000	USD
CY2016Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2015Q4	us-gaap	Goodwill Goodwill	936000	USD
CY2016Q3	us-gaap	Goodwill Goodwill	936000	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	4710000	USD
CY2016Q3	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2015Q3	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	4710000	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2486000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	9628000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	3879000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1284000	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	144339000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	118460000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-30646000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-45294000	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	38761000	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	38800000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1246000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1200000	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6500000	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6467000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6000000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5994000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1172000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3278000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5540000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	712000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1912000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	822000	USD
CY2016Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2015Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	2642160	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	2642160	shares
CY2016Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2015Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-695000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-7415000	USD
CY2016Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-299000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-609000	USD
CY2015Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2247000	USD
CY2016Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2475000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	2536000	USD
CY2016Q3	us-gaap	Inventory Net InventoryNet	3253000	USD
CY2015Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	289000	USD
CY2016Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	778000	USD
CY2015Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	300000	USD
CY2016Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	600000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	212293000	USD
CY2016Q3	us-gaap	Liabilities Liabilities	224825000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	512264000	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	532420000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	86981000	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	85994000	USD
CY2015Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5237000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2225000	USD
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	USD
CY2016Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	5212000	USD
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	5212000	USD
CY2015Q4	us-gaap	Marketable Securities MarketableSecurities	191799000	USD
CY2016Q3	us-gaap	Marketable Securities MarketableSecurities	250408000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	100370000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1195000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	19859000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-20215000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	2163000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	5167000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	105578000	USD
	us-gaap	Net Income Loss NetIncomeLoss	119706000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-37113000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-39300000	USD
CY2015Q3	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	76105000	USD
	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	121259000	USD
CY2016Q3	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-37113000	USD
	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-39300000	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	164835000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	154006000	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10274000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5302000	USD
CY2015Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	46849000	USD
CY2016Q3	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	46526000	USD
CY2015Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	45573000	USD
CY2016Q3	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	0	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	48501000	USD
	us-gaap	Operating Expenses OperatingExpenses	104990000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	54317000	USD
	us-gaap	Operating Expenses OperatingExpenses	136257000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-20496000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-35546000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Rolling After Year Five OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive	5019000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-20372000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-39992000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	10663000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Four And Five OperatingLeasesFutureMinimumPaymentsDueInRollingYearFourAndFive	1218000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Two And Three OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwoAndThree	3138000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Next Rolling Twelve Months OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths	1288000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1859000	USD
CY2016Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1974000	USD
CY2015Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-876000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-4395000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	308000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-397000	USD
CY2015Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	958000	USD
CY2016Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1143000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3066000	USD
CY2016Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2461000	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-314000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	35000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	151000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	156000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9500000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	94793000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	152016000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	33430000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	500000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	5271000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	7632000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	35000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	61000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2016Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2378000	USD
CY2016Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3553000	USD
CY2015Q4	us-gaap	Prepaid Taxes PrepaidTaxes	8107000	USD
CY2016Q3	us-gaap	Prepaid Taxes PrepaidTaxes	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	149454000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	4372000	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	5998000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	4977000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	92609000	USD
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	148411000	USD
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	USD
CY2016Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	5900000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6000000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	428000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	382000	USD
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	45000000	USD
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	1000000	USD
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	750000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14064000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34974000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18428000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50775000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-65153000	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-104453000	USD
CY2015Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	28005000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	69444000	USD
CY2016Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	33945000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	96265000	USD
CY2015Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22308000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	56856000	USD
CY2016Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	23848000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	66178000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	18748000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	22034000	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3400000	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	14.41
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	299971000	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	307595000	USD
CY2015Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	0	USD
CY2016Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	3879000	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3300000	USD
CY2016Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1500000	USD
	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	-1800000	USD
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42752859	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36800536	shares
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36980356	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36728911	shares
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35741877	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32650408	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36980356	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36728911	shares
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#4c4c4c;font-style:normal;font-weight:bold;text-decoration:none;">BASIS OF PRESENTATION</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December 31, 2015</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (the “2015 10-K”) filed with the Securities and Exchange Commission (the “SEC”) on February 26, 2016, and amended on March 2, 2016. The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information, the instructions for Form 10-Q and the rules and regulations of the SEC. Accordingly, since they are interim statements, the accompanying condensed consolidated financial statements do not include all of the information and notes required by GAAP for annual financial statements, but reflect all adjustments consisting of normal, recurring adjustments, that are necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. Interim results are not necessarily indicative of the results that may be expected for any future periods. The </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December 31, 2015</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> balance sheet information was derived from the audited financial statements as of that date.</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"> </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Certain reclassifications have been made to the prior period consolidated financial statements to conform to the current period presentation.</font></div></div>
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#4c4c4c;font-style:normal;font-weight:bold;text-decoration:none;">DESCRIPTION OF BUSINESS</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#006ebf;font-style:normal;font-weight:bold;text-decoration:none;">Organization and Description of Business</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In this Quarterly Report on Form 10-Q, unless the context requires otherwise, the terms “we”, “our”, “us”, “Retrophin” and the “Company” refer to Retrophin, Inc., a Delaware corporation, as well as our direct and indirect subsidiaries. We are a fully integrated biopharmaceutical company with approximately </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">135</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> employees headquartered in San Diego, California </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. Our approach centers on our pipeline, featuring clinical-stage assets and pre-clinical discovery programs targeting rare diseases with significant unmet medical needs. Our research and development efforts are supported by revenues from the Company's marketed products, Chenodal</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">®</sup></font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, Cholbam</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">® </sup></font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">and Thiola</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">®</sup></font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In addition we regularly evaluate and, where appropriate, act on opportunities to expand our product pipeline through licenses and acquisitions of products in areas that will serve patients with serious, catastrophic or rare diseases and that we believe offer attractive growth characteristics. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;">Products on the Market:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Chenodal</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">®</sup></font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (chenodeoxycholic acid) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been the standard of care for cerebrotendinous xanthomatosis (“CTX”) patients for more than three decades and the Company is currently pursuing adding this indication to the label.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Cholbam</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">®</sup></font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (cholic acid) is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Thiola</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">®</sup></font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (tiopronin) is approved in the United States for the prevention of cystine (kidney) stone formation in patients with homozygous cystinuria.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;">Product Candidates:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Sparsentan</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">,</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> also known as RE-021, is an investigational therapeutic agent which acts as both a potent angiotensin receptor blocker (“ARB”), as well as a selective endothelin receptor antagonist (“ERA”), </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">with in vitro selectivity toward endothelin receptor type A</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. We have secured a license to sparsentan from Ligand Pharmaceuticals, Inc. and Bristol-Myers Squibb Company (who referred to it as DARA). We are developing sparsentan as a treatment for </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">focal segmental glomerulosclerosis ("FSGS")</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, which is a leading cause of end-stage renal disease and Nephrotic Syndrome (“NS”). There are no U.S. Food and Drug Administration ("FDA") approved pharmacological treatments for FSGS and the off-label armamentarium is limited to ACE/ARBs, steroids, and immunosuppressant agents, which are effective in only a subset of patients. In the third quarter of 2016, we announced positive top-line data from the Phase 2 DUET study of sparsentan for the treatment of FSGS. We will work with the FDA in the near future to determine the most expeditious path forward to gain approval for sparsentan. Sparsentan was granted orphan drug designation in the U.S. and EU in January 2015 and November 2015, respectively.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We are developing RE-024, a novel small molecule, as a potential treatment for </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">pantothenate kinase-associated neurodegeneration ("</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">PKAN"). PKAN is a genetic neurodegenerative disorder that is typically diagnosed in the first decade of life. Consequences of PKAN include dystonia, dysarthria, rigidity, retinal degeneration, and severe digestive problems. There are currently no viable treatment options for patients with PKAN. RE-024 is a phosphopantothenate prodrug therapy that aims to restore levels of this key substrate in PKAN patients. Certain international health regulators have approved the initiation of dosing RE-024 in PKAN patients under physician-initiated studies in accordance with local regulations in their respective countries. The Company filed a Investigational New Drug application ("U.S. IND") for RE-024 with the FDA in the first quarter of 2015 to support the commencement of a Company-sponsored Phase 1 study, which was successfully completed during 2015. RE-024 was granted orphan drug designation by the FDA in May 2015 and was granted fast track designation by the FDA in June 2015. On February 24, 2016, we announced RE-024 was granted orphan drug designation from the European Commission. The Company continues discussions with the FDA and the European Medicines Agency ("EMA") regarding the initiation of a potential registration-enabling efficacy trial in PKAN patients.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">L-UDCA is a liquid formulation of ursodeoxycholic acid being developed for the treatment of a rare liver disease called primary biliary cholangitis ("PBC"). Retrophin expects to file a New Drug Application with the FDA in 2017 and, if approved, plans to make L-UDCA commercially available to the subset of PBC patients who have difficulty swallowing. There are no liquid formulations of ursodeoxycholic acid currently approved by the FDA.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">RE-034 is a synthetic hormone analog of the first 24 amino acids of the 39 amino acids contained in adrenocorticotropic hormone ("ACTH") incorporated into a novel formulation developed by the Company. RE-034 exhibits similar physiological actions as endogenous ACTH by binding to all five melanocortin receptors (pan-MCR), resulting in its anti-inflammatory and immunomodulatory effects. Retrophin has successfully manufactured RE-034 at proof-of-concept scale using a novel formulation process that allows modulation of the release of the active ingredient from the site of administration. The Company is exploring strategic options for development of RE-034, including the evaluation of external partnership and out-licensing opportunities.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;">Preclinical:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#006ebf;font-style:normal;font-weight:bold;text-decoration:none;">NGLY1</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company entered into a research collaboration with the Grace Science Foundation and the Warren Family Research Center for Drug Discovery and Development at the University of Notre Dame for the development of a novel therapeutic for patients with NGLY1 deficiency, a rare genetic disorder. NGLY1 deficiency is believed to be caused by a deficiency in an enzyme called N-glycanase-1, which is encoded by the gene NGLY1. The condition is characterized by a variety of symptoms, including global developmental delay, movement disorder, seizures, and ocular abnormalities. Under this collaboration, the Grace Science Foundation is providing support and funding to Retrophin to enable discovery efforts that aim to validate and address a new molecular target that may be relevant to NGLY1 deficiency. The Warren Family Research Center for Drug Discovery and Development at the University of Notre Dame is providing funding and in-kind research support to help Retrophin advance this program.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-16-020847-index-headers.html	Edgar Link	pending
0001628280-16-020847-index.html	Edgar Link	pending
0001628280-16-020847.txt	Edgar Link	pending
0001628280-16-020847-xbrl.zip	Edgar Link	pending
ex09302016101.htm	Edgar Link	pending
ex09302016102.htm	Edgar Link	pending
ex09302016311.htm	Edgar Link	pending
ex09302016312.htm	Edgar Link	pending
ex09302016321.htm	Edgar Link	pending
ex09302016322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pipelinechartq2a01.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rtrx-20160930.xml	Edgar Link	completed
rtrx-20160930.xsd	Edgar Link	pending
rtrx-20160930x10q.htm	Edgar Link	pending
rtrx-20160930_cal.xml	Edgar Link	unprocessable
rtrx-20160930_def.xml	Edgar Link	unprocessable
rtrx-20160930_lab.xml	Edgar Link	unprocessable
rtrx-20160930_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TVTX
Travere Therapeutics, Inc. Stock $tvtx

2016 Q4 Form 10-Q Financial Statement

#000162828016020847 Filed on November 04, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX Travere Therapeutics, Inc. Stock $tvtx

2016 Q4 Form 10-Q Financial Statement

#000162828016020847 Filed on November 04, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX
Travere Therapeutics, Inc. Stock $tvtx